Jubilant Ingrevia – A Gradual Turnaround in Progress?

While the specialty chemicals space remains structurally strong, Jubilant Ingrevia

shows mixed signals – improving profits but soft revenues. Positives EPS improving for 3 straight quarters. Profits rising QoQ for 4 consecutive quarters. Debt reduced from ₹829.25 Cr to ₹785.52 Cr. FIIs slightly bullish – raised stake from 6.89% to 7.12%. Technical bullish crossover – above 50 DMA. Still 15.71% below 52-week high – potential upside room. Concerns Revenue decline YoY and QoQ – muted top-line growth. Low ROE of 8.58% – capital not efficiently utilized. Annual EPS declined for 2 years. ROCE trending down – long-term profitability at risk. Stock trades at 3.51x book value – not cheap for the weak metrics. Below 20 DMA & 200 DMA – short- and long-term pressure remains. Bottom Line Jubilant Ingrevia is showing earnings recovery, but weak revenue traction and sub-par return ratios make it more of a watchlist candidate than a conviction buy. A breakout above 200 DMA with continued earnings momentum may change the game. If you found this post helpful, do follow me for more such insights!